Clinical trials: Second-Line
Carcinoma, Non-Small Cell Lung
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
The purpose of this study is to determine the potential benefit of adding Digoxin to erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.
- Trial name
- NCT00281021
- Testing
- Erlotinib plus Digoxin
- Volunteers
- 26 people
- Sponsor
- University of Louisville
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage…
- Trial name
- Pola-R-ICE (NCT04833114)
- Testing
- Polatuzumab Vedotin, Mabthera, Ifosfamide
- Where
- 64 sites in Austria, Germany and 2 more
- Volunteers
- 306 people
- Sponsor
- GWT-TUD GmbH
Pancreatic Adenocarcinoma Metastatic
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
A new approach that aims to destroy pancreatic tumor cells through modification of the tumor environment. Asparagine synthetase (ASNS) is an enzyme wich synthetise asparagine.
- Trial name
- NCT02195180
- Testing
- ERY001, Gemcitabine, 5-fluoro-uracil/oxaliplatin/leucovorin (folfox)
- Where
- 16 sites in France
- Volunteers
- 141 people
- Sponsor
- ERYtech Pharma
Medullary Thyroid Cancer (MTC), Differentiated Thyroid Cancer (DTC)
Nintedanib(BIBF1120) in Thyroid Cancer
For the treatment of thyroid cancer with the so called targeted therapy the angiogenesis pathway has several potential targets. The Receptors for Vascular endothelial growth factor (VEGF) and especially VEGFR-2 is considered to…
- Trial name
- NCT01788982
- Testing
- Nintedanib
- Where
- 27 sites in Belgium, Denmark and 7 more
- Volunteers
- 100 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Breast Cancer
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
This is a single-arm, phase Ib/II study to examine the safety, tolerability and preliminary efficacy of one cycle of Ad-RTS-hIL-12 immunotherapy in women with advanced breast cancer and pre-study SD or PR after completion of a…
- Trial name
- NCT02423902
- Testing
- Ad-RTS-hIL-12, Veledimex
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Alaunos Therapeutics
Colorectal Cancer
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways.
- Trial name
- NCT00940316
- Testing
- panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Pancreatic Cancer, Chemotherapy Effect
Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of LM-302 combined with gemcitabine as a second-line treatment for CLDN 18.2-positive unresectable locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT07108504
- Testing
- Gemcitabine, LM-302
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Ewing Sarcoma, Ewing Family of Tumors
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
The goal of this clinical trial was to compare participants with first relapse or refractory Ewing's sarcoma when treated with investigational product (Vigil) in addition to the standard treatment of irinotecan and temozolomide…
- Conditions
- Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- VITA (NCT03495921)
- Testing
- Vigil, Irinotecan, Temozolomide
- Where
- 15 sites in United States
- Volunteers
- 32 people
- Sponsor
- Gradalis, Inc.
Colorectal Cancer, Colorectal Neoplasms
Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status
Evaluate the efficacy and safety of Nocardia rubra cell wall skeleton in combination with prior second- or third-line regimens for the treatment of potentially hazardous colorectal cancer SD(Stable Disease) status in the real…
- Trial name
- NCT06356714
- Testing
- Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Sun Jing
Hepatitis C, Chronic
Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
To evaluate the safety, tolerability and immunogenicity of VGX-6150 as second-line therapy in chronic hepatitis C patients
- Trial name
- VGX-6150-01 (NCT02027116)
- Testing
- VGX-6150
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- GeneOne Life Science, Inc.
Head and Neck Squamous Cell Carcinoma
AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The administration of first-line pembrolizumab monotherapy or combined chemotherapy has been shown to improve survival among patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- Trial name
- NCT06508606
- Testing
- AK117 + Cetuximab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Multiple Myeloma
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
This study aims to compare how belantamab behaves in the body when given as an injection under the skin (SC) versus into a vein (IV) in participants with multiple myeloma who are receiving standard of care treatment, to enable…
- Trial name
- DynaMMic-2 (NCT07742527)
- Testing
- Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20)
- Volunteers
- 22 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered…
- Trial name
- NCT02508532
- Testing
- Avapritinib
- Where
- 19 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Blueprint Medicines Corporation
Recurrent Endometrial Cancer
A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma
Endometrial cancer (EC) is the 8th most common female cancer in Taiwan. Its incidence is increasing in the recent few years, around 1,200 new cases per year.
- Trial name
- NCT01454479
- Testing
- Lapatinib and ixempra
- Volunteers
- 24 people
- Sponsor
- Hung-Hsueh Chou
Pancreatic Cancer
Study of Gemcitabine and Abraxane for Pancreas Cancer
A Phase II trial of gemcitabine plus nab-paclitaxel in the second line setting
- Trial name
- NCT02242409
- Testing
- Gemcitabine and Abraxane
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Georgetown University
Small Cell Lung Cancer
SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013
The purpose of this study was to determine prospectively in all patients with SCLC in second line therapy that progression-free survival with the expected reintroduction of platinum / etoposide is greater progression-free…
- Trial name
- CBPC (NCT02738346)
- Testing
- Carboplatin, Etoposide, Topotecan
- Where
- France
- Volunteers
- 164 people
- Sponsor
- University Hospital, Angers
Metastatic Gastric Adenocarcinoma
A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma
This study evaluated the tolerance, safety and efficacy of Apatinib plus Docetaxel as the second-line treatment in locally advanced or metastatic gastric cancer (including Gastroesophageal junction (GEJ) Adenocarcinoma).
- Trial name
- NCT03071042
- Testing
- Apatinib, Docetaxel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sir Run Run Shaw Hospital
Myelodysplastic Syndrome
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
This protocol is a follow-up for patients receiving continuation of OPN-305 monotherapy treatment or combination treatment with azacitidine after completion of the dose confirming, dose expansion and HMA naïve parts of the main…
- Trial name
- NCT03337451
- Testing
- OPN-305
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Opsona Therapeutics Ltd.
Multiple Myeloma
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in combination with bortezomib and dexamethasone to placebo in combination with bortezomib and dexamethasone in the treatment of patients…
- Trial name
- NCT01470131
- Testing
- Masitinib, Bortezomib, Dexamethasone
- Where
- 13 sites in United States, France
- Volunteers
- 147 people
- Sponsor
- AB Science
Stomach Neoplasms
Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy
Phase II trial of AZD2014 in RICTOR amplified or overexpressed GC patients as second-line chemotherapy AZD2014 50mg BD continuous schedule of a 28 day cycle
- Trial name
- AZD2014 (NCT03061708)
- Testing
- AZD2014
- Where
- South Korea
- Volunteers
- 1 people
- Sponsor
- Samsung Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.